Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

Angiotensin Receptor Blockers May Help Prevent Dementia

HealthDay News
by -- Jane Parry
Updated: Jan 13th 2010

 

new article illustration

WEDNESDAY, Jan. 13 (HealthDay News) -- Angiotensin receptor blockers are associated with a significant reduction in the risk of developing Alzheimer's disease and dementia, along with a slowing of the progression of the disease in those who already have dementia, according to a study published online Jan. 12 in BMJ.

Nien-Chen Li, of the Boston University School of Public Health, and colleagues analyzed data from the 2002 to 2006 U.S. Veterans Affairs administrative database on 819,491 participants aged 65 and above with cardiovascular disease, of whom 98 percent were male. They compared the time to incident Alzheimer's disease for three groups of patients taking angiotensin receptor blockers, lisinopril, or other cardiovascular drugs.

Alzheimer's disease and dementia were significantly less likely among those taking angiotensin receptor blockers compared to those taking the other two classes of drugs, the investigators found. When taken in combination with angiotensin converting enzyme inhibitors, angiotensin receptor blockers were associated with a slower rate of decline among participants with existing Alzheimer's disease, the researchers discovered.

"The present study is the first to compare both risk of dementia and progression of dementia in users of angiotensin receptor blockers compared with users of a drug from the same class or users of other drugs prescribed for cardiovascular disease," the authors write. "Regardless of the mechanism, our study suggests that selective blockade of the angiotensin II receptor AT1 offers important health benefits to those with cognitive decline."

Several authors of the study received funding via grants from the Retirement Research Foundation and the Casten Foundation.

Abstract
Full Text
Editorial




Family Service & Community Mental Health Center
4100 Veterans Parkway
McHenry, IL  60050 [map]

815-385-6400


powered by centersite dot net